Clinical trial
Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular…
NCT02740972 · NS Pharma, Inc., Industry · Completed
Key facts
| NCT number | NCT02740972 |
|---|---|
| Title | Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD) |
| Official title | A Phase II, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD) |
| Lead sponsor | NS Pharma, Inc., Industry |
| Collaborators | Nippon Shinyaku Co., Ltd. Industry Cooperative International Neuromuscular Research Group Therapeutic Research in Neuromuscular Disorders Solutions |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Duchenne Muscular Dystrophy |
| Intervention type | Drug |
| Interventions | NS-065/NCNP-01, Placebo |
| Enrollment | 16 |
| Start date | Dec 1, 2016 |
| Primary completion | Mar 1, 2018 |
| Completion | Apr 1, 2018 |
| First posted | Apr 15, 2016 |
| Last update posted | Dec 7, 2021 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: